Optimal Dosing of Piperacillin‐Tazobactam for the Treatment of Pseudomonas aeruginosa Infections: Prolonged or Continuous Infusion?

Study Objective. To compare conventional intermittent dosing regimens of piperacillin‐tazobactam with prolonged and continuous infusions to determine the optimal dosing scheme against a local Pseudomonas aeruginosa population.

[1]  D. Livermore,et al.  Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  G. Drusano,et al.  Pharmacodynamic Profiling of Piperacillin in the Presence of Tazobactam in Patients through the Use of Population Pharmacokinetic Models and Monte Carlo Simulation , 2004, Antimicrobial Agents and Chemotherapy.

[3]  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. , 2004, American journal of infection control.

[4]  K. Itani,et al.  Randomized, Open-Label, Comparative Study of Piperacillin-Tazobactam Administered by Continuous Infusion versus Intermittent Infusion for Treatment of Hospitalized Patients with Complicated Intra-Abdominal Infection , 2006, Antimicrobial Agents and Chemotherapy.

[5]  J. Kuti.  Divergence in MIC Distributions of Pseudomonas aeruginosa for Piperacillin and Piperacillin/Tazobactam , 2001 .

[6]  D. Nicolau,et al.  Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. , 2005, The Journal of antimicrobial chemotherapy.

[7]  G. Drusano,et al.  Application of Antimicrobial Pharmacodynamic Concepts into Clinical Practice: Focus on β‐Lactam Antibiotics , 2006 .

[8]  G. Drusano,et al.  Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. , 2006, Pharmacotherapy.

[9]  D. Nicolau,et al.  Pharmacodynamic Target Attainment of Six β‐Lactams and Two Fluoroquinolones Against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella Species Collected from United States Intensive Care Units in 2004 , 2007, Pharmacotherapy.

[10]  D. Nicolau,et al.  Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. , 2002, Diagnostic microbiology and infectious disease.

[11]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[12]  D. Nicolau,et al.  Clinical Efficacy and Pharmacoeconomics of a Continuous‐Infusion Piperacillin‐Tazobactam Program in a Large Community Teaching Hospital , 2002, Pharmacotherapy.

[13]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .

[14]  Ronald N. Jones,et al.  Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). , 2007, Diagnostic microbiology and infectious disease.

[15]  J. Turnidge.  The pharmacodynamics of beta-lactams. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  Ronald N. Jones,et al.  Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  G. Drusano,et al.  Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  D. Nicolau,et al.  Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. , 2007, Diagnostic microbiology and infectious disease.

[19]  George L. Drusano,et al.  Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' , 2004, Nature Reviews Microbiology.

[20]  J. Turnidge.  The Pharmacodynamics of β-Lactams , 1998 .

[21]  G L Drusano,et al.  Prevention of resistance: a goal for dose selection for antimicrobial agents. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  J. Aeschlimann.  The Role of Multidrug Efflux Pumps in the Antibiotic Resistance of Pseudomonas aeruginosa and Other Gram‐Negative Bacteria , 2003, Pharmacotherapy.